Skip to content

Released May 7, 2026, after the close

10-Q filed May 7, 2026, 37 days after period end · 0001193125-26-211987

Q1 2026 · 10-Q
Revenue$8.21M−12.8% vs Q1 2025−80.7% vs Q4 2025
Net Income-$9.08MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.54N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$11,370,000N/M
Operating Cash Flow-$22,097,000N/M
Free Cash Flowderived-$22,116,000N/M
Margins · derived
Operating margin-138.4%−32.9 pt vs Q1 2025
Net margin-110.5%−16.9 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$8.21M$9.42M$5.79M$0.00
Net Income-$9.08M-$8.82M-$9.08M-$18.95M
EPS Diluted-$0.54-$1.17-$1.66-$4.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR